Abstract:

Peritoneal Dialysis is one of the treatments for end⁃stage renal disease（ESRD）. Although the peritoneum can be used as a biodialysis membrane to remove metabolic waste，the annual mortality rate in peritoneal dialytic patients is still high，and the progressive fibrosis of the peritoneum has shortened the application cycle of peritoneal dialysis. Through non⁃targeted and targeted metabonomics studies on the serum of peritoneal dialysis patients，we could find the differential metabolites of patients with adequate peritoneal dialysis and inadequate peri⁃ toneal dialysis. Previous studies have shown that certain metabolite such as trimethylamine N⁃oxide，canine Urine and citrulline，tryptophan metabolite 5⁃methoxytryptophan（5⁃MTP）is the most promising biomarker metabolite for the detection of early CKD；CA125，IL⁃6 and Plasminogen Activator inhibitor 1（PAI⁃1），VEGF，and MMP2 arepossible biomarkers of peritoneal fibrosis. Therefore，various metabolomics methods are implemented to identify metabolites and metabolic pathways related to peritoneal dialysis，and has positive significance for the diagnosis and treatment in Chronic Kidney Disease patients. Metabolomics research is expected to discover pathways related to the disease process.

Key words:

peritoneal dialysis, metabolomics, pathogenesis, metabolic pathway, biomakers